EP3520776A1 — Dosage forms of apixaban
Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2019-08-07 · 7y expired
What this patent protects
The present invention provides a process for producing a solid amorphous dispersion of apixaban comprising dissolving apixaban and one or more polymers in a solvent, which dissolves both apixaban and the one or more polymers and removing the solvent by spray drying; a solid amorp…
USPTO Abstract
The present invention provides a process for producing a solid amorphous dispersion of apixaban comprising dissolving apixaban and one or more polymers in a solvent, which dissolves both apixaban and the one or more polymers and removing the solvent by spray drying; a solid amorphous dispersion prepared according to the process; as well as a dosage form comprising the solid amorphous dispersion.
Drugs covered by this patent
- Eliquis (apixaban) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.